Streptococcus Pneumoniae

RVX-001 is a novel and cost-effective protein-based vaccine against pneumococcal invasive disease, a tripartite pneumococcal vaccine that provides universal coverage through antibody- and cell-mediated responses.


Streptococcus pneumoniae (or the pneumococcus) is one of the primary causes of life threatening diseases such as pneumonia, meningitis and sepsis, accounting for over 1.9 million deaths worldwide. The bacterium exists in more than 100 distinct variants (known as serotypes), which vary in their biological properties and distribution around the globe.

The bacterium spreads through contact with people who carry the bacteria in their nose and throat e.g., via respiratory droplets. People, especially children, can be carriers without showing any signs of disease, and can then spread the bacterium to others. As such, vaccines are the best way to prevent pneumococcal disease.

Our Research

We assessed the protective efficacy and immunogenicity of RVX-001 in murine models of invasive pneumococcal disease (IPD) using both adult and infant mice, testing various formulations including human licensed adjuvants, protein combinations and doses, in challenge experiments with vaccine and non-vaccine covered serotypes. Prevnar13® (Pfizer) was used as our benchmark vaccine throughout our investigations. While we confirmed that Prevnar13® is a robust vaccine, our results showed that RVX-001 offered cross-serotype protection beyond those covered by Prevnar13®. We determined that this effect was largely due to protein-specific cell-mediated immune responses.

Get in touch

To learn more about our RVX-001 Streptococcus Pneumoniae vaccine please click on the below button